{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:37:06Z","timestamp":1791232626428,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"Objectives<\/jats:title>This study aimed to investigate the protection of the salivary glands by vitamin C administration at 2 and 24\u2005h after an initial treatment using iodine-131 (131<\/jats:sup>I) in patients with differentiated thyroid cancer (DTC) and examined the optimal administration time of vitamin C to protect the salivary glands from radiation injury.<\/jats:p><\/jats:sec>Method<\/jats:title>The clinical data of patients with differentiated thyroid carcinoma who had been treated with 131<\/jats:sup>I in the Department of Nuclear Medicine in Shanxi Bethune Hospital from January 2014 to December 2020 were retrospectively analyzed. The propensity score matching method was adopted to match patients who received the administration of vitamin C at 2\u2005h with those receiving administration at 24\u2005h. A total of 230 pairs\/460 patients were enrolled in the study. The chi-squared (\u03c7<\/jats:italic>2<\/jats:sup>) or Fisher's exact test was used to compare the indicators representing the incidence of salivary gland injury between the two groups.<\/jats:p><\/jats:sec>Results<\/jats:title>The incidence of salivary gland injury (17.39%) with acidic substances at 2\u2005h was lower compared with administration at 24\u2005h (26.96%). The incidence of acute salivary gland injury (15.22%) and chronic salivary gland injury (26.09%) in the 24-h group were higher than those in the 2-h group (4.78% and 18.26%, respectively). The differences in the left submandibular gland concentrate index and right submandibular gland concentrate index were statistically significant before and after treatment in both the 2 and the 24-h groups; these functions had been impaired after treatment.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Following treatment with 131<\/jats:sup>I, the protective effect of acidic substances administered at 2 and 24\u2005h on the salivary glands were different. The incidence of salivary gland injury in the 2\u2005h acid stimulation group was lower than in the 24\u2005h acid stimulation group. The present study revealed that 131<\/jats:sup>I treatment did cause some injury to the salivary glands and that the protective effect of administering vitamin C at 2 and 24\u2005h may be limited. Accordingly, protection against salivary gland injury should be conducted using comprehensive measures.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fsurg.2022.993712","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T04:26:13Z","timestamp":1663820773000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Optimal administration time of vitamin C after 131I therapy in differentiated thyroid cancer based on propensity score matching"],"prefix":"10.3389","volume":"9","author":[{"given":"Ye","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000432397","article-title":"Radioiodine treatment and thyroid hormone suppression therapy for differentiated thyroid carcinoma: adverse effects support the trend toward less aggressive treatment for low-risk patients","volume":"4","author":"Klein Hesselink","year":"2015","journal-title":"Eur Thyroid J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1210\/jcem.84.11.6117","article-title":"Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands","volume":"84","author":"Spitzweg","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4274\/2017.26.suppl.11","article-title":"The thyroid Na+\/I- symporter: molecular characterization and genomic regulation","volume":"26","author":"Alotaibi","year":"2017","journal-title":"Mol Imaging Radionucl Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-021-00304-3","article-title":"Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand?","author":"Adramerinas","year":"2021","journal-title":"Hormones (Athens)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.clinimag.2014.12.018","article-title":"Salivary gland dysfunction after radioactive iodine (I-131) therapy in patients following total thyroidectomy: emphasis on radioactive iodine therapy dose","volume":"39","author":"Lee","year":"2015","journal-title":"Clin Imaging"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4376720","DOI":"10.1155\/2016\/4376720","article-title":"Short-term side effects after radioiodine treatment in patients with differentiated thyroid cancer","volume":"2016","author":"Lu","year":"2016","journal-title":"Biomed Res Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bjoms.2014.01.025","article-title":"Sialoendoscopy: a viable treatment for I(131) induced sialoadenitis","volume":"52","author":"De Luca","year":"2014","journal-title":"Br J Oral Maxillofac Surg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.2967\/jnumed.108.061382","article-title":"Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation","volume":"50","author":"Grewal","year":"2009","journal-title":"J Nucl Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1601-0825.2010.01726.x","article-title":"Sialoadenitis secondary to (1)(3)(1)I therapy for well-differentiated thyroid cancer","volume":"17","author":"Van Nostrand","year":"2011","journal-title":"Oral Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"E227","DOI":"10.1002\/hed.23974","article-title":"Effect of recombinant human thyroid-stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation","volume":"38","author":"Iakovou","year":"2016","journal-title":"Head Neck"},{"key":"B12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40658-014-0100-1","article-title":"Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy (124)I PET\/CT imaging","volume":"1","author":"Jentzen","year":"2014","journal-title":"EJNMMI Phys"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00259-010-1532-z","article-title":"The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(\/CT) imaging","volume":"37","author":"Jentzen","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B14","first-page":"261","article-title":"Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?","volume":"46","author":"Nakada","year":"2005","journal-title":"J Nucl Med"},{"key":"B15","first-page":"64","article-title":"Quantitative evaluation of salivary gland scintigraphy in Sjorgen\u2019s syndrome","volume":"40","author":"Umehara","year":"1999","journal-title":"J Nucl Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/BF02984967","article-title":"Scoring analysis of salivary gland scintigraphy in patients with Sjogren\u2019s syndrome","volume":"17","author":"Shizukuishi","year":"2003","journal-title":"Ann Nucl Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ctrv.2015.09.001","article-title":"Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma\u2013a systematic review","volume":"41","author":"Clement","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1016\/j.ultrasmedbio.2015.06.010","article-title":"Ultrasonographic features of the major salivary glands after radioactive iodine ablation in patients with papillary thyroid carcinoma","volume":"41","author":"Kim","year":"2015","journal-title":"Ultrasound Med Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/00003072-200211000-00003","article-title":"Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment","volume":"27","author":"Caglar","year":"2002","journal-title":"Clin Nucl Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1002\/hed.26417","article-title":"Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophthalmology, nuclear medicine and endocrinology","volume":"42","author":"Singer","year":"2020","journal-title":"Head Neck"},{"key":"B21","first-page":"149","article-title":"Radiation parotitis from radioactive iodine therapy","volume":"30","author":"Rigler","year":"1955","journal-title":"Proc Staff Meet Mayo Clin"},{"key":"B22","first-page":"13","article-title":"[Studies on newly recognized chronic sialadenitis]","volume":"54","author":"Yu","year":"2022","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijom.2021.11.003","article-title":"Differences between radioactive iodine-induced sialadenitis and chronic obstructive parotitis","author":"Li","year":"","journal-title":"Int J Oral Maxillofac Surg"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1016\/j.ultrasmedbio.2021.05.013","article-title":"Progressive changes in the major salivary gland after radioiodine therapy for differentiated thyroid cancer: a single-center retrospective ultrasound cohort study","volume":"47","author":"Huang","year":"2021","journal-title":"Ultrasound Med Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/MNM.0000000000000325","article-title":"Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up","volume":"36","author":"Wu","year":"2015","journal-title":"Nucl Med Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/00006231-200606000-00004","article-title":"Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy","volume":"27","author":"Raza","year":"2006","journal-title":"Nucl Med Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14219\/jada.archive.1991.0098","article-title":"How much saliva is enough? \u201cNormal\u201d function defined","volume":"122","author":"Ship","year":"1991","journal-title":"J Am Dent Assoc"},{"key":"B28","doi-asserted-by":"publisher","first-page":"618","DOI":"10.2967\/jnumed.109.071449","article-title":"Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial","volume":"51","author":"Liu","year":"2010","journal-title":"J Nucl Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1007\/s00259-009-1351-2","article-title":"Pre-therapeutic (124)I PET(\/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer","volume":"37","author":"Jentzen","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B30","doi-asserted-by":"publisher","first-page":"546","DOI":"10.2967\/jnumed.107.049411","article-title":"Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine","volume":"49","author":"Silberstein","year":"2008","journal-title":"J Nucl Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1089\/thy.2009.0429","article-title":"Radiopharmacokinetics of radioiodine in the parotid glands after the administration of lemon juice","volume":"20","author":"Van Nostrand","year":"2010","journal-title":"Thyroid"},{"key":"B32","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/MNM.0000000000000034","article-title":"Does lemon juice increase radioiodine reaccumulation within the parotid glands more than if lemon juice is not administered?","volume":"35","author":"Kulkarni","year":"2014","journal-title":"Nucl Med Commun"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1210\/jc.2016-1605","article-title":"Risk factors of (131)I-induced salivary gland damage in thyroid cancer patients","volume":"101","author":"Hollingsworth","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","first-page":"1551","article-title":"Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma","volume":"39","author":"Alexander","year":"1998","journal-title":"J Nucl Med"},{"key":"B35","first-page":"738","article-title":"Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy","volume":"42","author":"Solans","year":"2001","journal-title":"J Nucl Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s12149-013-0697-5","article-title":"Symptomatic late-onset sialadenitis after radioiodine therapy in thyroid cancer","volume":"27","author":"An","year":"2013","journal-title":"Ann Nucl Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s12149-013-0735-3","article-title":"Prediction of risk for symptomatic sialadenitis by post-therapeutic dual (131)I scintigraphy in patients with differentiated thyroid cancer","volume":"27","author":"Lee","year":"2013","journal-title":"Ann Nucl Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.clon.2006.11.005","article-title":"Salivary gland toxicity after radioiodine therapy for thyroid cancer","volume":"19","author":"Hyer","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1089\/thy.2012.0106","article-title":"Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms","volume":"23","author":"Jeong","year":"2013","journal-title":"Thyroid"},{"key":"B40","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/eos.12689","article-title":"Scintigraphic evaluation of salivary gland function in thyroid cancer patients after radioiodine remnant ablation","volume":"128","author":"Krcalova","year":"2020","journal-title":"Eur J Oral Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"TC23","DOI":"10.7860\/JCDR\/2017\/27340.10431","article-title":"A functional scoring system based on salivary gland scintigraphy for evaluating salivary gland dysfunction secondary to (131)I therapy in patients with differentiated thyroid carcinoma","volume":"11","author":"Maruoka","year":"2017","journal-title":"J Clin Diagn Res"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.993712\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T04:26:24Z","timestamp":1663820784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.993712\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":41,"alternative-id":["10.3389\/fsurg.2022.993712"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2022.993712","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]},"article-number":"993712"}}